Rezolute (RZLT) Cash from Financing Activities (2010 - 2026)

Rezolute recorded quarterly Cash from Financing Activities of $747000.0 in Q1 2026, up 109.83% quarter-over-quarter from $356000.0 in Q4 2025, and up 7370.0% year-over-year from $10000.0 in Q1 2025.

Rezolute's Cash from Financing Activities history runs 16 years deep, the most recent figure standing at $747000.0 for Q1 2026.

  • In Q1 2026, Cash from Financing Activities rose 7370.0% year-over-year to $747000.0; the TTM figure through Mar 2026 stood at $103.2 million (up 48.47% YoY), while the FY2025 annual figure was $107.3 million, up 70.28% from the prior year.
  • Cash from Financing Activities came in at $747000.0 for Q1 2026 at Rezolute, up from $356000.0 in the prior quarter.
  • In the past five years, Cash from Financing Activities ranged from a high of $101.2 million in Q2 2025 to a low of -$19000.0 in Q1 2022.
  • A 4-year average of $23.2 million and a median of $829000.0 in 2025 frame the typical range for Cash from Financing Activities.
  • Across the five-year window, Cash from Financing Activities plunged 83.44% in 2025 and soared 7370.0% in 2026, its largest moves.
  • Rezolute's Cash from Financing Activities stood at $11.6 million in 2022, then tumbled by 94.32% to $657000.0 in 2024, then sank by 45.81% to $356000.0 in 2025, then surged by 109.83% to $747000.0 in 2026.
  • According to Business Quant data, Cash from Financing Activities over the past three periods registered $747000.0, $356000.0, and $911000.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Cash from Financing Activities (Qtr)
1 Quantum Biopharma 961,148.99 Bn 961,148.98 Bn - 7.00 Mn
2 Alterity Therapeutics 744,933.29 Bn 744,933.26 Bn - -
3 Legend Biotech 2,540.00 Bn 2,539.71 Bn 242.10 Mn -600,000.00
4 Nanobiotix 2,199.85 Bn 2,199.78 Bn - -
5 Akari Therapeutics 1,635.88 Bn 1,635.88 Bn - 53,000.00
6 Vertex Pharmaceuticals 111.32 Bn 104.07 Bn 2.59 Bn -538.80 Mn
7 Evaxion A 62.56 Bn 62.54 Bn - -
8 Regeneron Pharmaceuticals 62.55 Bn 53.79 Bn 3.31 Bn -802.20 Mn
9 Alnylam Pharmaceuticals 39.57 Bn 36.56 Bn 959.66 Mn 15.71 Mn
10 Rezolute 374.41 Mn 374.41 Mn - 747,000.00

Historic Data

Download Data 🔒
DateValue
Mar 31, 2026 747,000.00
Mar 31, 2026 747,000.00
Dec 31, 2025 356,000.00
Dec 31, 2025 356,000.00
Sep 30, 2025 911,000.00
Sep 30, 2025 911,000.00
Jun 30, 2025 101.16 Mn
Jun 30, 2025 101.16 Mn
Mar 31, 2025 10,000.00
Mar 31, 2025 10,000.00
Dec 31, 2024 657,000.00
Dec 31, 2024 657,000.00
Sep 30, 2024 5.50 Mn
Sep 30, 2024 5.50 Mn
Jun 30, 2024 63.33 Mn
Jun 30, 2024 63.33 Mn
Mar 31, 2024 -3,000.00
Mar 31, 2024 -3,000.00
Sep 30, 2022 11.57 Mn
Sep 30, 2022 11.57 Mn
Jun 30, 2022 94.10 Mn
Jun 30, 2022 94.10 Mn
Mar 31, 2022 -19,000.00
Mar 31, 2022 -19,000.00
Dec 31, 2021 52.31 Mn
Dec 31, 2021 52.31 Mn
Sep 30, 2021 2.59 Mn
Sep 30, 2021 2.59 Mn
Jun 30, 2021 14.29 Mn
Jun 30, 2021 14.29 Mn
Mar 31, 2021 -214,000.00
Mar 31, 2021 -214,000.00
Dec 31, 2020 37.46 Mn
Dec 31, 2020 37.46 Mn
Dec 31, 2019 -21,000.00
Dec 31, 2019 -21,000.00
Sep 30, 2019 22.57 Mn
Sep 30, 2019 22.57 Mn
Mar 31, 2019 23.50 Mn
Mar 31, 2019 23.50 Mn
Dec 31, 2018 1.50 Mn
Dec 31, 2018 1.50 Mn
Jun 30, 2018 3.90 Mn
Jun 30, 2018 3.90 Mn
Mar 31, 2018 1.20 Mn
Mar 31, 2018 1.20 Mn
Sep 30, 2017 4.44 Mn
Sep 30, 2017 4.44 Mn
Jun 30, 2017 3.78 Mn
Jun 30, 2017 3.78 Mn
Mar 31, 2017 4.50 Mn
Mar 31, 2017 4.50 Mn
Dec 31, 2016 3.32 Mn
Dec 31, 2016 3.32 Mn
Sep 30, 2016 2.33 Mn
Sep 30, 2016 2.33 Mn
Jun 30, 2016 5.79 Mn
Jun 30, 2016 5.79 Mn
Mar 31, 2016 3.09 Mn
Mar 31, 2016 3.09 Mn
Dec 31, 2015 1.87 Mn
Dec 31, 2015 1.87 Mn
Sep 30, 2015 -23,109.00
Sep 30, 2015 -23,109.00
Jun 30, 2015 1.25 Mn
Jun 30, 2015 1.25 Mn
Mar 31, 2015 2.60 Mn
Mar 31, 2015 2.60 Mn
Dec 31, 2014 6.18 Mn
Dec 31, 2014 6.18 Mn
Jun 30, 2014 3.21 Mn
Jun 30, 2014 3.21 Mn
Mar 31, 2014 5.21 Mn
Mar 31, 2014 5.21 Mn
Dec 31, 2013 1.51 Mn
Dec 31, 2013 1.51 Mn
Jun 30, 2013 -157,500.00
Jun 30, 2013 -157,500.00
Mar 31, 2013 270,000.00
Mar 31, 2013 270,000.00
Dec 31, 2012 630,000.00
Dec 31, 2012 630,000.00
Sep 30, 2012 675,000.00
Sep 30, 2012 675,000.00
Jun 30, 2012 760,500.00
Jun 30, 2012 760,500.00
Mar 31, 2012 1.16 Mn
Mar 31, 2012 1.16 Mn
Dec 31, 2011 735,700.00
Dec 31, 2011 735,700.00
Sep 30, 2011 41,800.00
Sep 30, 2011 41,800.00
Dec 31, 2010 13,800.00
Dec 31, 2010 13,800.00
Sep 30, 2010 28,000.00
Sep 30, 2010 28,000.00